Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During…
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is…
-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567…
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients…
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and…
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE…
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare…
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE…
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG…